Amended recombinant cells (ARCs) expressing bovine IFN-gamma: an economical and highly effective adjuvant system.


:Interferon-gamma (IFN-gamma) has potent immune stimulatory activity, but purifying recombinant protein is expensive, soluble cytokine delivery is inefficient, and high doses of IFN-gamma cause adverse systemic effects. We've shown, however, that chemically fixed, amended recombinant Pseudomonas fluorescens cells (ARCs), expressing soluble bovine IFN-gamma (BGI/ARCs), provide an effective production and delivery vehicle for highly active cytokine. In this report we investigate the immune enhancing activity of BGI/ARCs in the presence or absence of two other adjuvants which enhance cell recruitment and protein uptake. Adjuvant activity and immune-mediated protection was evaluated using recombinant, truncated glycoprotein-D (tgD) and a bovine herpesvirus-1 (BHV-1) disease challenge. Our initial dose-titration study showed that 100 microg of recombinant IFN-gamma in BGI/ARCs significantly increased both IgG1 and IgG2 tgD-specific antibody titres and IgG1/IgG2 ratios were significantly reduced with as little as 1.0 microg IFN-gamma. Vaccine formulation studies, using 20 microg tgD/vaccine dose and 100 microg IFN-gamma delivered in BGI/ARCs, formulated in phosphate buffered saline (PBS), induced significantly increased antibody responses, following both primary and secondary immunization, and immune-mediated protection following a BHV-1 respiratory infection. Co-formulating BGI/ARCs with either an oil and water emulsion (Emulsigen) or a polyphosphazene polymer (PCPP) did not significantly enhance tgD-specific antibody titres or disease protection when compared with BGI/ARCs alone. Surprisingly, co-delivering a single dose of BGI/ARCs with tgD protein in PBS had optimal adjuvant activity and the dose of IFN-gamma delivered was four-fold less than the dose previously shown to induce adverse systemic responses.






Gaertner FH,Babiuk LA,Mutwiri G,Armstrong JM,Griebel PJ




Has Abstract


2009-02-25 00:00:00
















  • A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.

    abstract::This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 and tuberculin skin t...


    pub_type: 杂志文章,随机对照试验


    authors: Odutola AA,Owolabi OA,Owiafe PK,McShane H,Ota MO

    更新日期:2012-08-17 00:00:00

  • Deinococcus Mn2+-peptide complex: A novel approach to alphavirus vaccine development.

    abstract::Over the last ten years, Chikungunya virus (CHIKV), an Old World alphavirus has caused numerous outbreaks in Asian and European countries and the Americas, making it an emerging pathogen of great global health importance. Venezuelan equine encephalitis virus (VEEV), a New World alphavirus, on the other hand, has been ...


    pub_type: 杂志文章


    authors: Gayen M,Gupta P,Morazzani EM,Gaidamakova EK,Knollmann-Ritschel B,Daly MJ,Glass PJ,Maheshwari RK

    更新日期:2017-06-22 00:00:00

  • Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.

    abstract::Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP-HepB-Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag beh...


    pub_type: 杂志文章


    authors: Suarez-Castaneda E,Burnett E,Elas M,Baltrons R,Pezzoli L,Flannery B,Kleinbaum D,de Oliveira LH,Danovaro-Holliday MC

    更新日期:2015-11-27 00:00:00

  • Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis.

    abstract::Consumed for centuries, lactic acid bacteria are excellent candidates for the development of safe mucosal delivery vehicles for prophylactic and therapeutic molecules. We have recently reported that the immune response to an effective OspA-expressing L. plantarum vaccine for Lyme disease is modulated by the lipid modi...


    pub_type: 杂志文章


    authors: del Rio B,Fuente JL,Neves V,Dattwyler R,Seegers JF,Gomes-Solecki M

    更新日期:2010-09-24 00:00:00

  • Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

    abstract::The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between ...


    pub_type: 杂志文章


    authors: Ng KW,Pearton M,Coulman S,Anstey A,Gateley C,Morrissey A,Allender C,Birchall J

    更新日期:2009-10-09 00:00:00

  • Immunoprophylaxis against important virus disease of horses, farm animals and birds.

    abstract::Since the refinement of tissue culture techniques for virus isolation and propagation from the mid 1960s onwards, veterinary virology has received much academic and industrial interest, and has now become a major global industry largely centred on vaccine development against economically important virus diseases of fo...


    pub_type: 杂志文章,评审


    authors: Patel JR,Heldens JG

    更新日期:2009-03-13 00:00:00

  • Age-dependent tolerance to an endogenous tumor-associated antigen.

    abstract::Immunologic tolerance to endogenous antigens reduces antitumor responses. Gp70 is an endogenous tumor-associated antigen (TAA) of the BALB/c-derived colon carcinoma CT26. We found that expression of gp70 mRNA is detectable in tissues of mice 8 months of age and older. We showed that expression of gp70 establishes immu...


    pub_type: 杂志文章


    authors: McWilliams JA,Sullivan RT,Jordan KR,McMahan RH,Kemmler CB,McDuffie M,Slansky JE

    更新日期:2008-03-28 00:00:00

  • RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

    abstract:BACKGROUND:We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen. METHODS:The primary objective was to assess...


    pub_type: 杂志文章


    authors: Doener F,Hong HS,Meyer I,Tadjalli-Mehr K,Daehling A,Heidenreich R,Koch SD,Fotin-Mleczek M,Gnad-Vogt U

    更新日期:2019-03-22 00:00:00

  • Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

    abstract::Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective...


    pub_type: 杂志文章,评审


    authors: Garcia-Angulo VA,Kalita A,Torres AG

    更新日期:2013-07-11 00:00:00

  • Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens.

    abstract::Susceptible dairy cattle were immunized with attenuated, live calf-derived, in vitro-cultured or biologically cloned Babesia bovis, with non-viable exoantigens, or with recombinant rhoptry-associated protein 1 (rRAP1). Antibody response assessed by the indirect fluorescent assay (IFA) and by the growth inhibition acti...


    pub_type: 临床试验,杂志文章


    authors: Fish L,Leibovich B,Krigel Y,McElwain T,Shkap V

    更新日期:2008-12-19 00:00:00

  • Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake.

    abstract:BACKGROUND:Vaccine coverage estimates lag by years in the US. Commercially available medical claims databases contain timely records of childhood vaccinations given in physician offices. We used such data to track the replacement of the 7-valent pneumococcal conjugate vaccine (PCV7) by PCV13, a new vaccine active again...


    pub_type: 杂志文章


    authors: Schuck-Paim C,Taylor R,Lindley D,Klugman KP,Simonsen L

    更新日期:2013-12-05 00:00:00

  • Avian influenza virus: of virus and bird ecology.

    abstract::The recent introductions of highly pathogenic avian influenza (HPAI) H5N1 virus in wild birds and its subsequent spread throughout Asia, the Middle East, Africa and Europe has put a focus on the role of wild birds in the geographical spread of HPAI H5N1 virus. Large-scale surveillance programs are ongoing to determine...


    pub_type: 杂志文章,评审


    authors: Munster VJ,Fouchier RA

    更新日期:2009-10-23 00:00:00

  • Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.

    abstract:BACKGROUND:This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-t...


    pub_type: 杂志文章,随机对照试验


    authors: Herasimtschuk A,Downey J,Nelson M,Moyle G,Mandalia S,Sikut R,Adojaan M,Stanescu I,Gotch F,Imami N

    更新日期:2014-12-05 00:00:00

  • Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

    abstract::Pfs25, a Plasmodium falciparum surface protein expressed during zygote and ookinete stages in infected mosquitoes, is a lead transmission-blocking vaccine candidate against falciparum malaria. To enhance immunogenicity, recombinant Pfs25 was chemically conjugated to recombinant nontoxic Pseudomonas aeruginosa ExoProte...


    pub_type: 杂志文章


    authors: Zhu D,Wu Y,McClellan H,Dai W,Rausch K,Jones D,Aebig J,Barnafo E,Butler B,Lambert L,Narum DL,Duffy PE

    更新日期:2017-05-31 00:00:00

  • A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.

    abstract::In order to prevent hepatitis B virus (HBV) infection of infants of hepatitis B surface antigen (HBsAg)-positive mothers, a nation-wide immunization programme was initiated in Italy in January 1984. During the first 3 years (1984-86), 651,667 out of 1726,000 pregnant women (37.8%) were screened for HBsAg; the percenta...


    pub_type: 杂志文章


    authors: Stroffolini T,Pasquini P,Mele A

    更新日期:1989-04-01 00:00:00

  • Development and characterization of a live attenuated influenza B virus vaccine candidate.

    abstract::A human influenza B/Lee/40 virus was cold-adapted by serial passages in embryonated chicken eggs, at progressively lower temperatures, for possible use as a future influenza B vaccine donor strain. Temperature sensitive and cold-adapted phenotypes were achieved as a consequence of the adaptation process. It was determ...


    pub_type: 杂志文章


    authors: Seo SU,Byun YH,Lee EY,Jung EJ,Jang YH,Kim HA,Ha SH,Lee KH,Seong BL

    更新日期:2008-02-13 00:00:00

  • Vaccines and Internet: characteristics of the vaccine safety net web sites and suggested improvements.

    abstract:UNLABELLED:The Internet contains a large amount of useful information on many subjects, but also information of doubtful quality. To help identify Web sites on vaccine safety that fulfil good practice, the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO) has published criteria to which...


    pub_type: 杂志文章


    authors: Martínez-Mora M,Alvarez-Pasquín MJ,Rodríguez-Salvanés F

    更新日期:2008-12-09 00:00:00

  • National surveillance of invasive pneumococcal diseases in Taiwan, 2008-2012: differential temporal emergence of serotype 19A.

    abstract:INTRODUCTION:Serotype replacement after the introduction of seven-valent pneumococcal conjugate vaccine (PCV7) and the future availability of multivalent PCVs prompted the listing of invasive pneumococcal disease (IPD) as a notifiable disease in Taiwan in October 2007. Here, we report the national surveillance results....


    pub_type: 杂志文章


    authors: Chiang CS,Chen YY,Jiang SF,Liu DP,Kao PH,Teng HJ,Kuo TL,Yao SM,Tseng LR,Wang YL,Wu HS,Chang FY,Lin TY

    更新日期:2014-06-05 00:00:00

  • Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

    abstract:BACKGROUND:Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear. METHODS:ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10...


    pub_type: 杂志文章


    authors: Shive CL,Judge CJ,Clagett B,Kalayjian RC,Osborn M,Sherman KE,Fichtenbaum C,Gandhi RT,Kang M,Popkin DL,Sieg SF,Lederman MM,Rodriguez B,Anthony DD

    更新日期:2018-01-25 00:00:00

  • Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.

    abstract::To study the regulation of the human immune response to hepatitis B surface antigen (HBsAg) we have carefully monitored the in vivo humoral and in vitro cellular immune responses to HBsAg in 50 subjects receiving four doses of hepatitis B vaccine according to a 0, 1, 2, 12 month vaccination scheme. Twenty-three subjec...


    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Leroux-Roels G,Van Hecke E,Michielsen W,Voet P,Hauser P,Pêtre J

    更新日期:1994-07-01 00:00:00

  • Introduction to the supplement.

    abstract::In July of 2014, a symposium entitled "Enhancing Vaccine Immunity and Value" was held in Siena, Italy. The focus of the symposium was on how to best meet the challenge of developing and implementing vaccines for future disease targets. Vaccination has been responsible for averting estimated 3 billion cases of disease ...


    pub_type: 社论


    authors: Rappuoli R

    更新日期:2015-06-08 00:00:00

  • Induction of humoral immune response against Pseudomonas aeruginosa flagellin(1-161) using gold nanoparticles as an adjuvant.

    abstract::Flagellin of Pseudomonas aeruginosa is an important vaccine candidate. N-terminal domains are highly conserved in both type a and type b flagellins. The efficacy of gold nanoparticles (AuNPs) conjugated to N-terminal domains of P. aeruginosa flagellin (flagellin(1-161)), as an immunogen in mice, has been assessed. The...


    pub_type: 杂志文章


    authors: Dakterzada F,Mohabati Mobarez A,Habibi Roudkenar M,Mohsenifar A

    更新日期:2016-03-14 00:00:00

  • An alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling.

    abstract::Type I IFN and IL-12 are well documented to serve as so called "signal 3" cytokines, capable of facilitating CD8(+) T cell proliferation, effector function and memory formation. While their ability to serve in this capacity is well established, to date, no non-cytokine signal 3 mediators have been clearly identified. ...


    pub_type: 杂志文章


    authors: Sanchez PJ,Kedl RM

    更新日期:2012-02-01 00:00:00

  • Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines.

    abstract::Cell substrate DNA was shown to be an abundant contaminant in the clarified preparations of the Sabin type 1, 2 and 3 poliovaccines produced on a continuous cell line (4647). The size of the DNA, as evaluated for the Sabin type 1 poliovaccine, was highly heterogeneous, ranging from 100 to 20,000 base pairs. In view of...


    pub_type: 杂志文章


    authors: Amosenko FA,Svitkin YV,Popova VD,Terletskaya EN,Timofeev AV,Elbert LB,Lashkevich VA,Drozdov SG

    更新日期:1991-03-01 00:00:00

  • Cost and cost-effectiveness of childhood vaccination against rotavirus in France.

    abstract:OBJECTIVES:To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. METHODS:We constructed a Markov decision tree to compare two alternatives: "no vaccination" and "vaccination". A hypothetical birth cohort of 750,000 children was followed until 3...


    pub_type: 杂志文章


    authors: Melliez H,Levybruhl D,Boelle PY,Dervaux B,Baron S,Yazdanpanah Y

    更新日期:2008-01-30 00:00:00

  • Evaluation of measles vaccination programme conducted in two separate health centres.

    abstract::Measles vaccination programmes at two vaccination centres in Ibadan, Nigeria were evaluated using the following factors as indicators: type of vaccination centre, age at vaccination, titre of vaccine, economic, health and social status of vaccinee. There was a significant association between type of vaccination centre...


    pub_type: 临床试验,杂志文章


    authors: Onoja AL,Adu FD,Tomori O

    更新日期:1992-01-01 00:00:00

  • Immunology of scorpion toxins and perspectives for generation of anti-venom vaccines.

    abstract::Scorpions and other venomous animals contain concentrates of biologically active substances developed to block vital physiological and biochemical functions of the victims. These have contrasting human health concerns, provide important pharmacological raw material and pose a serious threat to human life and health in...


    pub_type: 杂志文章,评审


    authors: Gazarian KG,Gazarian T,Hernández R,Possani LD

    更新日期:2005-05-16 00:00:00

  • Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

    abstract::Modified Vaccinia virus Ankara (MVA) is an attenuated strain of vaccinia virus that is being considered as a safer alternative to replicating vaccinia vaccine strains such as Dryvax(®) and ACAM2000. Its excellent safety profile and large genome also make it an attractive vector for the delivery of heterologous genes f...


    pub_type: 杂志文章


    authors: Hermanson G,Chun S,Felgner J,Tan X,Pablo J,Nakajima-Sasaki R,Molina DM,Felgner PL,Liang X,Davies DH

    更新日期:2012-01-11 00:00:00

  • Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

    abstract::A devastating disease spread by mosquitoes with high-efficiency, malaria imposes an enormous burden for which no licensed vaccine currently exists. Although the genome complexity of the parasite has made vaccine development tenuous, an effective malaria vaccine would be a valuable tool for control, elimination and eve...


    pub_type: 杂志文章,评审


    authors: Palacpac NM,Arisue N,Tougan T,Ishii KJ,Horii T

    更新日期:2011-08-11 00:00:00

  • The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.

    abstract::Clostridium difficile infection (CDI) causes nosocomial antibiotic-associated diarrhea and colitis in the developed world. Two potent cytotoxins, toxin A (TcdA) and toxin B (TcdB) are the virulence factors of this disease and can be a good vaccine candidate against CDI. In the present study, we genetically engineered ...


    pub_type: 杂志文章


    authors: Guo S,Yan W,McDonough SP,Lin N,Wu KJ,He H,Xiang H,Yang M,Moreira MA,Chang YF

    更新日期:2015-03-24 00:00:00